meprobamate tablet
taro pharmaceutical industries ltd. - meprobamate (unii: 9i7lny769q) (meprobamate - unii:9i7lny769q) - meprobamate 200 mg - meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic. the effectiveness of meprobamate tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. acute intermittent porphyria as well as allergic or idiosyncratic reactions to meprobamate or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal.
meprobamate tablet
alembic pharmaceuticals limited - meprobamate (unii: 9i7lny769q) (meprobamate - unii:9i7lny769q) - meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic. the effectiveness of meprobamate tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. acute intermittent porphyria as well as allergic or idiosyncratic reactions to meprobamate or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal.
meprobamate tablet
alembic pharmaceuticals inc. - meprobamate (unii: 9i7lny769q) (meprobamate - unii:9i7lny769q) - meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic. the effectiveness of meprobamate tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. acute intermittent porphyria as well as allergic or idiosyncratic reactions to meprobamate or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal.
meprobamate tablet
cipla usa inc. - meprobamate (unii: 9i7lny769q) (meprobamate - unii:9i7lny769q) - meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic. the effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. acute intermittent porphyria as well as allergic or idiosyncratic reactions to meprobamate or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal.
equanil® l.a. tablets
akromed -
equanil® tablets
akromed -
equagesic- meprobamate and aspirin tablet
mikart, inc. - meprobamate (unii: 9i7lny769q) (meprobamate - unii:9i7lny769q), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - tablet - 200 mg - as an adjunct in the short-term treatment of pain accompanied by tension and/or anxiety in patients with musculoskeletal disease. clinical trials have demonstrated that in these situations relief of pain is somewhat greater than with aspirin alone. equagesic is not intended for use longer than 10 days. usage in pregnancy and lactation an increased risk of congenital malformations associated with the use of minor tranquilizers (meprobamate, chlordiazepoxide, and diazepam) during the first trimester of pregnancy has been suggested in several studies. because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. because of the known effect of non-steroidal anti-inflammatory drugs (nsaids) on the fetal cardiovascular system (closure of the ductus arteriosus), use during the third trimester of pregnancy should be avoided. salicylate products have also been associated with alterations in maternal and neonatal hemostasis mechanisms, decreased birth weight, a
meprobamate tablet
watson laboratories, inc. - meprobamate (unii: 9i7lny769q) (meprobamate - unii:9i7lny769q) - meprobamate 200 mg
champix tablet
pfizer canada ulc - varenicline (varenicline tartrate) - tablet - 0.5mg - varenicline (varenicline tartrate) 0.5mg - miscellaneous autonomic drugs
champix tablet
pfizer canada ulc - varenicline (varenicline tartrate) - tablet - 1mg - varenicline (varenicline tartrate) 1mg - miscellaneous autonomic drugs